DUAL ANTIRETROVIRAL THERAPY WITH LOPINAVIR AND RITONAVIR
- Authors: Yurin O.G.1, KRAVCHENKO A.V1, KANESTRI V.G1, POKROVSKAYA A.V1, SHAKHGILDYAN V.I1, VOLKOVA S.B2
-
Affiliations:
- Federal Research and Guidance Center for Prevention and Control of AIDS and Infectious Diseases, Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Sverdlovsk Regional Center for Prevention and Control of AIDS and Infectious Diseases
- Issue: No 6 (2014)
- Pages: 38-41
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278131
- ID: 278131
Cite item
Open Access
Access granted
Abstract
Antiretroviral therapy regimens are multicomponent, i.e. they include at least three antiretrovirals. However, some or other drugs in the regimen are not always well tolerated by a patient in the short- or long-term period. Up to date, a large number of clinical trials have been conducted to simplify therapy regimens. This review gives the results of clinical trials of dual HIV protease inhibitor-containing regimens with lopinavir/ritonavir (LPV/r) that is most commonly used in Russian clinical practice and proposes recommendations for the use of dual therapy regimens containing LPV/r and RAL or LPR/r and 3TC in HIV-infected patients who have or have not previously received antiretroviral therapy.
Full Text
About the authors
Oleg G. Yurin
Federal Research and Guidance Center for Prevention and Control of AIDS and Infectious Diseases, Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: oleg_gerald@mail.ru
A. V KRAVCHENKO
Federal Research and Guidance Center for Prevention and Control of AIDS and Infectious Diseases, Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: kravtchenko@hivrussia.net
V. G KANESTRI
Federal Research and Guidance Center for Prevention and Control of AIDS and Infectious Diseases, Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: kanestry@yandex.ru
A. V POKROVSKAYA
Federal Research and Guidance Center for Prevention and Control of AIDS and Infectious Diseases, Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: pokrovskaya_av@mail.ru
V. I SHAKHGILDYAN
Federal Research and Guidance Center for Prevention and Control of AIDS and Infectious Diseases, Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: vishakh@yandex.ru
S. B VOLKOVA
Sverdlovsk Regional Center for Prevention and Control of AIDS and Infectious Diseases
Email: svetlana@olvo.ru
References
- Reynes J., Lawal A., Pulido F., Soto-Malave R., Gathe J., Tian M. et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the PROGRESS study, 48-week results. HIV Clin. Trials 2011; 12: 255-267.
- Reynes J., Trinh R., Pulido F., Soto-Malave R., Gathe J., Qaqish R. et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res. Hum.R.etrov. 2013; 29(2): 256-265.
- Qaqish R., Trinh R., Tian M., Fredrick L., Podsadecki T., Norton M. et al. Bone mineral density (BMD) analysis in antiretroviral (ART)-naïve subjects taking lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS study. Rome, IAS 2011. Abstract TULBPE021.
- SECOND-LINE Study Group.R.itonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a andomized, open-label, non-inferiority study. Lancet 2013; 381: 2091-2099.
- Martin A., Moore C., Mallon P.W.G., Hoy J., Emery S., Belloso W. et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS 2013; 27(15): 2403-2411.
- GARDEL Study Group. Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study. 14th European AIDS Conference (EACS 2013). Brussels, 2013. Abstract LBPS7/6.
- Rolon M.J., Figueroa M.I., Patterson P. et al. Dual therapy efficacy in key subgroups of treatment-naive patients in the GARDEL study. 20th International AIDS Conference. Melbourne, 2014. Abstract WEPE080
- Gatell J.M., Arribas J.R., Girard P.M., Landman R., Pich J., Mallolas J. et al. Non-inferiority of dual-therapy (DT) with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) vs tripletherapy (TT) with LPV/r plus two nucleos(t)ides (NRTIs) for maintenance of HIV-1 viral suppression: 48-week results of the OLE study. Program and abstracts of the 20th International AIDS Conference. Melbourne, 2014. Abstract LBPE17.
Supplementary files
